bs-12022R [Primary Antibody]
GPR17 Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: GPR17

Immunogen Range: 1-100/367


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 2840

Swiss Prot: Q13304

Source: KLH conjugated synthetic peptide derived from human GPR17

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background:

G protein-coupled receptor 17, GPR17, also known as uracil nucleotide/cysteinyl leukotriene receptor or P2Y-like receptor (P2YL), is a 367 amino acid member of the G-protein coupled receptor 1 family of proteins. While GPR17 is expressed in kidney, heart and umbilical vein endothelial cells, it is expressed in the highest levels in the brain. Upon brain injury, the extracellular concentrations of nucleotides and cysteinyl leukotrienes (CysLTs), two families of endogenous signaling molecules, increase significantly at the site of damage. In some neurons, GPR17, a membrane receptor for uracil nucleotide and CysLTs, is upregulated as well, infiltrating the lesioned area. GPR17 is thought to play a role in mediating neuronal death, remodeling brain circuitries by microglia and initiating remyelination in damaged neurons. Two named isoforms of GPR17 exist as a result of alternative splicing events.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)
IHC-P(1:200-400)
IHC-F(1:100-500)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)
ICC(1:100-500)

Predicted Molecular Weight: 41


Predicted Cross Reactive Species: Human
Mouse
Rat
Rabbit

For research use only. Not intended for diagnostic or therapeutic use.

VALIDATION IMAGES

Lane 1: Mouse Cerebrum tissue lysates; Lane 2: Mouse Cerebellum tissue lysates probed with GPR17 Polyclonal Antibody, Unconjugated (bs-12022R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.